The aim is to detect molecular characteristics of tumors with metastatic potential, focusing on the largest group of breast cancer patients, i.e., estrogen-receptor (ER) positive and human epidermal growth factor receptor 2 (HER2) negative tumors, with diverse prognoses, ranging from excellent to poor. Here, ESR1 is linked to breast carcinoma.